MetaCap

Entrada Therapeutics Inc. (TRDA)

NASDAQ: TRDAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

4.35-0.29 (-6.25%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TRDA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$170.30M
EPS (TTM)
-$3.84
52-week range
4.11 – 16.45
Day range
4.32 – 4.58
Volume / Avg
347.92K / 401.15K
Beta
—

52-week range

$4.11$16.45

TRDA stock today

On Nov 20, TRDA ended the session at $4.35, shedding $0.29 (6.25%), versus the S&P 500's 3.70% decline. Shares are 73.6% below their 52-week high of $16.45, set on May 6, 2026 and 5.9% above the 52-week low of $4.11, near the bottom of the past year's range. TRDA is down 57.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 57.0%.

Entrada Therapeutics has posted a net loss over the last twelve months (EPS of -$3.84), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Entrada Therapeutics

Company profile

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Dipal Doshi
Headquarters
Boston, MA
Employees
152
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, Entrada Therapeutics generated $25.4 million in revenue, down 87.9% from fiscal 2024, the first decline in the 6 years shown. Entrada Therapeutics reported a net loss of $143.8 million, compared with net income of $65.6 million a year earlier. Operating margin was -621.1%.

Entrada Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$25.42M$210.78M$129.01M——
Growth-87.94%+63.38%———
Net income$-143.75M$65.63M$-6.68M$-94.62M$-51.16M
EPS (diluted)$-3.47$1.68$-0.20$-3.02$-8.16

Analyst forecast

Forecast

Consensus (8 analysts)

strong_buy

Avg. price target

$17.75+308.05%

  • Strong buy 0
  • Buy 7
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $10.00High $25.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.94 vs $-0.98
Surprise
+4.08%

TRDA news

All TRDA news

Entrada Therapeutics peers

Health Care sector
TRDA peer companies
CompanyPrice% ChgMarket capCompare
SIGASIGA Technologies Inc.2.40-9.43%$172.45Mvs TRDA
KRROKorro Bio Inc.12.18-0.08%$167.18Mvs TRDA
ABEOAbeona Therapeutics Inc.2.42-1.22%$165.31Mvs TRDA
VOGXVogenx Inc11.87-7.30%$176.33Mvs TRDA
NATRNature's Sunshine Products Inc.10.18+0.10%$176.41Mvs TRDA
EMISEmmis Acquisition Corp. Class A10.36+0.15%$163.36Mvs TRDA
ADCTADC Therapeutics SA1.28-1.54%$180.05Mvs TRDA
SLGLSol-Gel Technologies Ltd.55.17+2.02%$180.63Mvs TRDA

Indexes, lists and sector

Entrada Therapeutics stock FAQ

What is Entrada Therapeutics's stock price today?

TRDA last traded at $4.35 as of Nov 20, 4:00 PM EST, down 6.25% on the day. Prices are delayed at least 15 minutes.

Who is Entrada Therapeutics's CEO?

Mr. Dipal Doshi is the chief executive officer of Entrada Therapeutics Inc., which has about 152 employees.

What is the TRDA 52-week high?

The 52-week high for TRDA is $16.45 and the 52-week low is $4.11. The stock is currently 73.6% below its high.

Compare TRDA